最近の記事
- 2019/02/14
- Frontiers in Systems Pharmacogy
- 2019/02/05
- Patient-Derived Cancer Xenograft-Driven Zebrafish-Based Drug Discovery and Precision Medicine
- 2019/01/01
- 謹賀新年２０１９次世代ゼブラフィッシュ創薬とプレシジョンメディシン
- 2018/12/03
- 腫瘍血管新生のプレシジョンメディシン
- 2018/11/20
- 第４回ゼブラフィッシュ・メダカ創薬研究会基調講演報告
- 2018/10/24
- 次世代ゼブラフィッシュ創薬とプレシジョンメディシン
- 2018/09/11
- ゼブラフィッシュ創薬とプレシジョンメディシン
- 2018/08/31
- ゼブラフィッシュ創薬とプレシジョン医療
| 2014/09/30 |
|
第135号 Flash News「がん治療の新たな光となる新規治療標的遺伝子を発見」
第135号 Flash Newsに9/18の記者会見の模様が掲載されました。
Abstract
Zinc finger, MYND-type containing 8 (ZMYND8) encodes a receptor for activated C-kinase protein. Here, we report that ZMYND8 promotes angiogenesis in prostate cancer xenografts in zebrafish, as well as tube formation in human umbilical vascular endothelial cell (HUVEC) cultures. Using transcriptome analyses, we found upregulation of ZMYND8 expression in both zebrafish prostate cancer xenografts and prostate cancer samples from patients. In vitro and in vivo ZMYND8 knockdown suppressed angiogenesis, whereas ZMYND8 overexpression enhanced angiogenesis. Notably, ZMYND8 induced vegfa mRNA expression selectively in prostate cancer xenografts. Integrated analysis of human and zebrafish transcriptomes, which identified ZMYND8, might be a powerful strategy to determine also other molecular targets for inhibiting prostate cancer progression.
関連リンク
- Zinc finger MYND-type containing 8 promotes tumour angiogenesis via induction of vascular endothelial growth factor-A expression
- ＰＤＦ
関連画像
